Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

Everything you need to know about agonising sickle cell disease and the ‘revolutionary’ new DNA therapy that's being rolled out on the NHS for free to patients ...

Global biopharmaceutical manufacturing firm Rentschler Biopharma will shutter its United Kingdom facility as the ...

CDMO Rentschler Biopharma is moving out of the cell and gene therapy space and putting more of its chips behind biologics. | The German manufacturer is ending operations at its Stevenage, U.K., site ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...